UPJOHN WINS UK HALCION LIBEL CASE

5 June 1994

US drugmaker Upjohn is the victor in a libel trial involving the controversial anxiolytic Halcion (triazolam - sales of which have drifted down from the $237 million high of 1991), which ended last week after four months of hearings in the UK High Court . The decision of the court rejected charges of dishonesty levelled by the BBC and by Ian Oswald, a vocal, long-time critic of the US company.

Upjohn brought the suits against the BBC and Prof Oswald in January 1992 as a result of allegations made on a BBC television program entitled The Halcion Nightmare, broadcast October 14, 1991, and against Prof Oswald for comments he made in a January 20, 1992, interview with the New York Times. A similar action against the Sunday Express was settled in October 1992, when the newspaper apologized to Upjohn.

In rejecting allegations made by the BBC and Prof Oswald, Justice Sir Anthony May said that "when Halcion is in issue, Prof Oswald's judgement of people and their intentions and motives is, in my view, seriously astray." However, all parties were criticized by Sir Anthony regarding various aspects of the allegations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight